Amgen Inc. (NASDAQ:AMGN) Stock Holdings Lowered by Mathes Company Inc.

Mathes Company Inc. trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 8.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,330 shares of the medical research company’s stock after selling 300 shares during the period. Mathes Company Inc.’s holdings in Amgen were worth $1,040,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. United Community Bank purchased a new position in Amgen in the 4th quarter worth about $29,000. Horizon Financial Services LLC purchased a new position in shares of Amgen in the first quarter worth approximately $28,000. nVerses Capital LLC acquired a new stake in shares of Amgen during the second quarter valued at approximately $31,000. Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen during the second quarter valued at approximately $33,000. Finally, FSA Wealth Management LLC lifted its position in shares of Amgen by 182.0% in the 1st quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 91 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Argus boosted their target price on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Bank of America upped their price target on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Royal Bank of Canada raised their price objective on Amgen from $332.00 to $362.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. Wells Fargo & Company downgraded Amgen from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Finally, TD Cowen raised their price target on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and an average price target of $327.28.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $332.92 on Thursday. The stock has a market capitalization of $178.59 billion, a P/E ratio of 47.56, a P/E/G ratio of 2.93 and a beta of 0.61. The business has a 50-day moving average of $329.22 and a two-hundred day moving average of $305.00. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. During the same quarter last year, the firm posted $5.00 earnings per share. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. On average, equities research analysts predict that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.70%. Amgen’s payout ratio is presently 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.